Morphocell Secures $50M to Advance Stem-Cell Liver Therapy
Laval, Québec, December 1, 2025 — Morphocell Technologies has announced the successful completion of its US$50 million Series A...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Laval, Québec, December 1, 2025 — Morphocell Technologies has announced the successful completion of its US$50 million Series A...
Ramat Gan, Israel, November 26, 2025 — Can-Fite BioPharma has announced key updates across its advanced-stage clinical pipeline ahead...
MOUNTAIN VIEW, Calif., November 4, 2025 — RenovoRx, Inc. (NASDAQ: RNXT), a life sciences company pioneering targeted oncology therapies...
SAN DIEGO, Sept. 29, 2025 — Oncolytics Biotech® Inc. (NASDAQ: ONCY) today announced a key update on its plan...
SAN FRANCISCO, Sept. 25, 2025 — Biostar Pharma’s core anticancer drug Utidelone has been granted Orphan Drug Designation (ODD)...
GRAND CAYMAN, Cayman Islands, Sept. 11, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA...
SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...
